Replies to post #12585 on Biotech Values

[io_io]

GTCB paper:

Dew, very interesting .....

"Although long-term anticoagulation treatment decreased the incidence of recurrent events by 80%, it also resulted in a risk of major hemorrhage of 0.8% per year."

What do we know about the risk of major hemorrhage in Atryn ? I presume it is not an "anticoagulation treatment" ? Is there scope for off-label use in this population (not having surgery, child-birth, etc) ?

Also, curious how they could state such a conclusion to the trial ..... 0.8% sounds like iike would be hard to prove with significance.